Gilead Sciences, Inc. $GILD Shares Acquired by Sagespring Wealth Partners LLC

Sagespring Wealth Partners LLC boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 28.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,351 shares of the biopharmaceutical company’s stock after buying an additional 3,848 shares during the quarter. Sagespring Wealth Partners LLC’s holdings in Gilead Sciences were worth $1,924,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in shares of Gilead Sciences by 1.7% in the 1st quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company’s stock worth $13,162,606,000 after purchasing an additional 1,942,433 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Gilead Sciences by 314.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock worth $1,647,484,000 after purchasing an additional 11,156,382 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Gilead Sciences by 12.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 13,755,481 shares of the biopharmaceutical company’s stock worth $1,541,302,000 after purchasing an additional 1,520,809 shares during the last quarter. Nuveen LLC bought a new stake in shares of Gilead Sciences in the 1st quarter worth about $620,415,000. Finally, Robeco Institutional Asset Management B.V. increased its position in shares of Gilead Sciences by 12.5% in the 2nd quarter. Robeco Institutional Asset Management B.V. now owns 3,742,656 shares of the biopharmaceutical company’s stock worth $414,948,000 after purchasing an additional 417,237 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analyst Ratings Changes

GILD has been the subject of several research analyst reports. Truist Financial raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and boosted their target price for the stock from $108.00 to $127.00 in a research report on Friday, August 8th. Dbs Bank raised shares of Gilead Sciences to a “moderate buy” rating in a research report on Friday, September 5th. Citigroup boosted their price objective on shares of Gilead Sciences from $125.00 to $135.00 and gave the company a “buy” rating in a research report on Wednesday, October 8th. Cantor Fitzgerald boosted their price objective on shares of Gilead Sciences from $129.00 to $135.00 and gave the company an “overweight” rating in a research report on Thursday, October 9th. Finally, Needham & Company LLC raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 price objective for the company in a research report on Friday, July 25th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $118.08.

Insiders Place Their Bets

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $118.53, for a total value of $3,318,840.00. Following the completion of the transaction, the insider owned 114,168 shares in the company, valued at approximately $13,532,333.04. This represents a 19.70% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction dated Thursday, August 28th. The stock was sold at an average price of $113.63, for a total transaction of $1,136,300.00. Following the completion of the transaction, the chief executive officer owned 595,725 shares of the company’s stock, valued at approximately $67,692,231.75. This trade represents a 1.65% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 66,000 shares of company stock worth $7,632,100. Insiders own 0.27% of the company’s stock.

Gilead Sciences Price Performance

NASDAQ GILD opened at $118.48 on Wednesday. Gilead Sciences, Inc. has a 52 week low of $84.80 and a 52 week high of $121.83. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The stock has a market cap of $147.01 billion, a price-to-earnings ratio of 23.60, a price-to-earnings-growth ratio of 0.80 and a beta of 0.34. The company has a 50-day moving average price of $114.84 and a two-hundred day moving average price of $110.35.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping the consensus estimate of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm had revenue of $7.08 billion during the quarter, compared to analysts’ expectations of $6.95 billion. During the same quarter in the prior year, the firm earned $2.01 EPS. Gilead Sciences’s quarterly revenue was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were given a $0.79 dividend. The ex-dividend date was Monday, September 15th. This represents a $3.16 annualized dividend and a yield of 2.7%. Gilead Sciences’s dividend payout ratio is 62.95%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.